Browse the evidence

Adiponectin levels are reduced in obesity and are associated with insulin resistance, while higher levels of adiponectin (particularly HMW forms) correlate with improved insulin sensitivity and fatty acid oxidation.

Adiponectin is an 'anti-diabetic' hormone produced by fat cells. Unlike leptin, its levels drop when you are obese. Higher levels, especially the high-molecular-weight form, are linked to better insulin sensitivity and fat burning. Weight loss and exercise can help restore these levels.

Sarcopenia is defined by the presence of both low muscle mass and low muscle function (strength or physical performance).

To diagnose sarcopenia, you need both low muscle mass and low muscle function (strength or performance).

Obesity causes restrictive lung disease patterns (reduced ERV, FRC, TLC) primarily through mechanical restriction from adipose tissue deposition on the chest and abdomen, rather than intrinsic airway obstruction.

Your breathing difficulties are likely due to the physical weight of fat on your chest and abdomen restricting your lungs, not necessarily a disease like asthma. This 'restrictive' pattern means your lungs can't expand fully. Losing weight reduces this physical burden, allowing your lungs to expand more easily and improving your capacity. This is distinct from obstructive diseases where airways are narrowed.

Metabolic dysfunction (Metabolic Syndrome) significantly increases CHD risk regardless of body weight, with metabolically unhealthy normal weight individuals having more than double the risk of metabolically healthy normal weight individuals.

If you are normal weight, you are not immune to heart disease. If you have high blood pressure, high triglycerides, low HDL, high blood sugar, or a large waist, your risk is more than double that of a normal weight person with healthy metabolic markers. Address these metabolic issues through lifestyle changes or medication.

Day-to-day variation in food intake means that short-term measurements (e.g., 24 hours) are unlikely to reflect habitual intake, requiring statistical adjustment or multiple days of data for accurate assessment.

If you want to know your habitual diet, track for multiple days or use statistical methods to adjust for day-to-day variation. A single day's record is not enough to represent your long-term habits.

The doubly labelled water (DLW) method provides a highly accurate and precise measure of energy expenditure in free-living subjects, serving as a gold standard for validating energy intake assessments.

The doubly labelled water method is the gold standard for measuring energy expenditure in free-living subjects, but its high cost and complexity limit its routine use. Alternative validation methods like the EI/BMR ratio are available.

Reducing dietary saturated fatty acid intake leads to a decrease in HDL cholesterol, with the magnitude of decrease depending on the degree of SFA reduction.

Lowering saturated fat will lower your HDL ('good') cholesterol. However, it lowers LDL ('bad') cholesterol more significantly, which is the primary goal for heart health. This effect is consistent across most demographic groups.

In East Asians, a body mass index (BMI) of 25.0 or higher is associated with a significantly increased risk of cardiovascular disease mortality, with the lowest risk observed in the BMI range of 20.0-22.4.

If you are East Asian, maintaining a BMI between 20.0 and 22.4 is associated with the lowest risk of cardiovascular death. A BMI of 25 or higher is linked to increased risk, suggesting that standard Western 'overweight' thresholds may be too high for this demographic. Focus on maintaining a healthy weight through balanced nutrition and physical activity, rather than aiming for the lowest possible BMI, as very low BMI (<17.5) is also associated with higher CVD risk.

Adherence to an energy-unrestricted Mediterranean diet supplemented with extra-virgin olive oil or nuts significantly increases the likelihood of metabolic syndrome reversion compared to a low-fat diet, without preventing new-onset incidence.

If you are at high risk for heart disease or metabolic syndrome, switching to a Mediterranean diet rich in olive oil or nuts can help reverse your condition, even if you do not lose weight. Focus on adding these specific fats to your diet rather than restricting calories. While this may not stop new cases of metabolic syndrome from developing, it significantly increases your chances of reversing existing symptoms like central obesity and high blood sugar.

Physical inactivity is a major global health risk, ranking as the fourth leading cause of mortality and contributing to 3.2 million deaths annually, primarily through cardiovascular disease, diabetes, hypertension, and certain cancers.

Recognize that physical inactivity is a critical health risk, comparable to smoking or obesity. Prioritize increasing daily movement to reduce the risk of cardiovascular disease, diabetes, and hypertension. In Arab countries, be aware that cultural and gender-specific barriers may exist, requiring tailored solutions to overcome them.

Obesity is the primary environmental factor driving insulin resistance and the pathogenesis of Type 2 Diabetes (T2D) through mechanisms involving visceral fat distribution, ectopic lipid deposition, and gut microbiome dysbiosis.

Focus on reducing visceral and ectopic fat through sustainable lifestyle changes, as this is the most effective way to improve insulin sensitivity and prevent Type 2 Diabetes. Prioritize weight management, especially in high-risk groups, as it is the primary driver of the disease.

Critical Power (CP) is the gold standard for defining the maximal metabolic steady state, whereas Maximal Lactate Steady State (MLSS) systematically underestimates this threshold due to methodological limitations.

Stop using Maximal Lactate Steady State (MLSS) or arbitrary 60-minute functional thresholds as your primary guide for endurance capacity. Instead, determine your Critical Power (CP) using a power-duration curve model. CP accurately separates the 'heavy' intensity domain (where homeostasis is possible) from the 'severe' domain (where fatigue is inevitable). Training prescriptions based on CP are more physiologically robust than those based on MLSS, which tends to underestimate your true sustainable power.

Second-generation antipsychotics, particularly clozapine and olanzapine, cause significant weight gain in patients with schizophrenia, driven by increased caloric intake (orexigenic effects) and potentially altered energy expenditure.

If you are taking clozapine or olanzapine for schizophrenia, expect significant weight gain due to biological changes in hunger and food preference, not just lifestyle. This is a known side effect of the medication, not a personal failure. Proactive management with behavioral interventions and potentially switching to lower-risk medications (if clinically appropriate) is necessary.

Metformin is the most effective pharmacological adjunct for treating antipsychotic-induced weight gain, resulting in significant weight loss compared to placebo.

If you are gaining weight on antipsychotics, ask your doctor about metformin. It is the most proven medication to help counteract this specific type of weight gain and has a good safety profile. It works best when combined with lifestyle changes.

Low energy availability (EA < 30 kcal/kg FFM/day) in female athletes is associated with reduced blood glucose levels and altered hormone profiles, including lower T3 and elevated cortisol.

Severe energy deficiency can disrupt your hormones and blood sugar. If you are not eating enough to support your training, your body may lower thyroid hormone levels and increase stress hormones like cortisol, which can further impact your health and performance.

Oral semaglutide (up to 14 mg daily) significantly reduces the risk of major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes, specifically those with established atherosclerotic cardiovascular disease or chronic kidney disease.

If you have type 2 diabetes and existing heart disease or kidney issues, taking oral semaglutide (up to 14 mg daily) alongside your standard care significantly lowers your risk of heart attack, stroke, or cardiovascular death compared to a placebo. This benefit is achieved without increasing serious side effects, making it a viable option for cardiovascular risk reduction in this high-risk group.

Vitamin D status influences muscle function through genomic mechanisms involving the Vitamin D Receptor (VDR) and non-genomic rapid calcium handling.

Understanding that Vitamin D acts directly on muscle cells via specific receptors helps explain why deficiency leads to weakness. It is not just about bones.

Metformin reduces the risk of progression from prediabetes to type 2 diabetes by enhancing insulin action in the liver and skeletal muscle, with efficacy approaching that of intensive lifestyle intervention in younger, higher-BMI, or higher-FPG subgroups.

If you have prediabetes, metformin is a proven, safe, and low-cost option to delay or prevent type 2 diabetes. It works best if you are younger, overweight, or have higher fasting glucose. It should be used alongside lifestyle changes, not as a replacement, and requires a prescription.

Dietary phytate is a potent inhibitor of zinc absorption, significantly reducing fractional zinc absorption when the phytate:zinc molar ratio exceeds 15.

If your diet is plant-based, high phytate content (found in grains and legumes) can block up to 45% of zinc absorption if the phytate:zinc ratio is high. To improve zinc status, consider soaking, fermenting, or sprouting grains/legumes to reduce phytate, or include animal products which have higher zinc bioavailability.

Activation of the melanocortin-4 receptor (MC4R) by alpha-melanocyte-stimulating hormone (alpha-MSH) decreases energy intake and increases energy expenditure.

Your brain uses a specific hormonal pathway (leptin/insulin -> POMC -> MC4R) to regulate hunger and energy use. When this system works, it helps you stop eating and burn energy. Disruptions in this pathway (due to genetics or obesity) can make this harder, but the mechanism itself is a valid target for understanding appetite control.

GLP-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE), cardiovascular mortality, and all-cause mortality in patients with type 2 diabetes, particularly those with established cardiovascular disease.

If you have Type 2 Diabetes and existing heart disease or high risk, GLP-1 receptor agonists (like liraglutide or semaglutide) are proven to significantly lower your risk of heart attack, stroke, and death. This benefit exists alongside blood sugar control. However, if you have heart failure with reduced ejection fraction, these drugs may increase risks, so discuss your specific heart condition with your doctor before starting.

Semaglutide has a favorable cardiovascular safety profile, with cardiovascular outcome trials (SUSTAIN-6, PIONEER-6) showing no increased risk of major adverse cardiovascular events (MACE) compared to placebo.

Semaglutide is safe for your heart. Large studies have shown it does not increase the risk of heart attack, stroke, or cardiovascular death in people with type 2 diabetes, and may even offer benefits.

HMB supplementation is safe in humans, with no adverse effects on blood chemistry, hematology, or organ function at doses up to 3-4 g/day.

HMB is safe for human consumption at doses used for muscle building (up to 4g/day), with no negative impacts on liver, kidney, or blood markers.

Insulin and leptin function as redundant adiposity signals to the brain, where they share downstream melanocortin signaling pathways to regulate food intake and energy expenditure.

Your body uses insulin and leptin to tell your brain how much fat you have stored. When these signals are high, your brain reduces hunger and increases energy use. When they are low (fasting/weight loss), hunger increases. This is a biological defense mechanism, not a failure of willpower.